We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00965835
Recruitment Status : Unknown
Verified December 2009 by National Institute on Aging (NIA).
Recruitment status was:  Recruiting
First Posted : August 26, 2009
Last Update Posted : December 29, 2009
Information provided by:
National Institute on Aging (NIA)

Brief Summary:
The purpose of this study is to develop small molecule radio-labeled probes of beta-amyloid, to be used with positron emission tomography (PET) for early detection and treatment monitoring of Alzheimer disease (AD). The study hypothesis is that PET imaging of small molecule probes, in the form of novel fluorescent dyes with radioactive labels, will demonstrate cerebral patterns in patients with AD that are distinct from those of age-matched persons who are cognitively intact.

Condition or disease
Down Syndrome Alzheimer's Disease

Detailed Description:
This is a naturalistic study in which clinical evaluations and brain scans will be performed on 20 people with Down syndrome (DS) as well as 20 healthy controls across a range of ages. Participants will receive comprehensive clinical and neuropsychological assessments. PET and MRI scans will be performed at baseline and after two years of follow up. All participants will have blood drawn for APOE genotyping during their baseline evaluations. The intellectual range of participants with DS will be restricted to IQ scores of 45 to 60 (moderate range) to reduce variability, particularly due to extreme low levels of intellectual ability.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome
Study Start Date : August 2009
Estimated Primary Completion Date : May 2011
Estimated Study Completion Date : May 2011

Those with Down syndrome
Healthy controls

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Individuals will be identified and recruited using IRB approved flyers distributed to treating clinicians, caregivers from Board and Care homes, sheltered workshop administrators (where potential participants are employed), and representatives of County Regional Centers (primary evaluation and treatment centers for developmentally delayed individuals).

Inclusion Criteria:

  • Age 21 years or older
  • No significant cerebrovascular disease - modified Ischemic Score of < 4
  • Adequate visual and auditory acuity to allow neuropsychological testing
  • Screening laboratory tests and ECG without significant abnormalities that might interfere with the study

Additional Inclusion Criteria for Controls

  • MMSE score between 24 and 30 (unless < 8 years of educational achievement)
  • The following medications are allowed if stable for > 1 month: antidepressants (without anticholinergic effects) if not currently depressed and no history of major depression for 2 years; estrogen replacement therapy; thyroid replacement therapy as long as individual is euthyroid; antihypertensives that do not influence cognitive function

Additional Inclusion Criteria for Individuals with Down syndrome

  • Family member or caregiver available; caregiver relationship 2 years or longer
  • Karyotype DX of trisomy or translocation DS Mosaic form of Down syndrome
  • English-speaking

Exclusion Criteria:

  • Evidence of neurological or other physical illness that could produce cognitive deterioration; volunteers with a history of TIAs, carotid bruits, or lacunes on MRI scan will be excluded
  • Parkinson's Disease
  • History of myocardial infarction within the previous year or unstable cardiac disease
  • Uncontrolled hypertension (systolic BP > 170 or diastolic BP > 100), history of significant liver disease, clinically significant pulmonary disease, diabetes, or cancer
  • Major psychiatric disorders, such as bipolar disorder or schizophrenia
  • Medicines that could influence psychometric test results
  • Use of any of the following drugs: centrally active beta-blockers, narcotics, clonidine, anti-Parkinsonian medications, benzodiazepines, systemic corticosteroids, medications with significant cholinergic or anticholinergic effects, anti-convulsants, or warfarin
  • Current diagnosis or history of alcoholism or drug dependence
  • Evidence of untreated depression or untreated anxiety
  • Use of any investigational drugs within the previous month or longer, depending on drug half-life
  • Contraindication for MRI scan (e.g., metal in body, claustrophobia)
  • Diagnosis of possible or probable AD or any other dementia (e.g., vascular, Lewy body, frontotemporal) or MCI

Additional Exclusion Criteria for Individuals with Down syndrome

  • Mosaic form of Down syndrome
  • History of clinically significant neurological disorder or disease and Psychiatric diagnosis or treatment within 3 months prior to screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00965835

Layout table for location contacts
Contact: Andrea Kaplan 310-825-0545 akaplan@mednet.ucla.edu
Contact: Deborah Dorsey, RN 310-825-0545 ddorsey@mednet.ucla.edu

Layout table for location information
United States, California
UCLA Recruiting
Los Angeles, California, United States, 90024
Contact: Andrea Kaplan, BA    310-825-0545    akaplan@mednet.ucla.edu   
Contact: Deborah Dorsey, RN, MN    310-825-0545    ddorsey@mednet.ucla.edu   
Principal Investigator: Linda Nelson, PhD         
Sponsors and Collaborators
National Institute on Aging (NIA)
Layout table for investigator information
Principal Investigator: Linda Nelson, PhD Semel Institute, UCLA
Layout table for additonal information
Responsible Party: Linda Nelson, Ph.D., Emerita, Professor of Psychiatry and Biobehavioral Sciences, Semel Institute
ClinicalTrials.gov Identifier: NCT00965835    
Other Study ID Numbers: IA0166
1R21AG030681-01A2 ( U.S. NIH Grant/Contract )
First Posted: August 26, 2009    Key Record Dates
Last Update Posted: December 29, 2009
Last Verified: December 2009
Keywords provided by National Institute on Aging (NIA):
PET Scan
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Down Syndrome
Plaque, Amyloid
Pathologic Processes
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Pathological Conditions, Anatomical